德康医疗(DXCM)周四盘后股价大跌15.26%,主要原因是该公司重申了较为保守的2024年全年销售额预期,引发投资者对公司未来增长前景的担忧。
德康医疗当天公布的第三季度财报显示,公司实现营收3.45亿美元,同比增长29%,超出华尔街预期。这主要得益于其连续性血糖监测(CGM)设备在糖尿病患者中的强劲需求。
然而,尽管第三季度业绩亮眼,德康医疗仍然重申了2024年全年销售额约为40亿至40.5亿美元的预期。部分分析师认为这一预期略显保守,意味着公司增长可能放缓,从而引发投资者对公司未来发展前景的担忧,最终导致盘后大幅抛售该股票,股价大跌15.26%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.